| Literature DB >> 23330637 |
Weijun Shen1, Matthew S Tremblay, Vishal A Deshmukh, Weidong Wang, Christophe M Filippi, George Harb, You-qing Zhang, Anwesh Kamireddy, Janine E Baaten, Qihui Jin, Tom Wu, Jonathan G Swoboda, Charles Y Cho, Jing Li, Bryan A Laffitte, Peter McNamara, Richard Glynne, Xu Wu, Ann E Herman, Peter G Schultz.
Abstract
The identification of factors that promote β cell proliferation could ultimately move type 1 diabetes treatment away from insulin injection therapy and toward a cure. We have performed high-throughput, cell-based screens using rodent β cell lines to identify molecules that induce proliferation of β cells. Herein we report the discovery and characterization of WS6, a novel small molecule that promotes β cell proliferation in rodent and human primary islets. In the RIP-DTA mouse model of β cell ablation, WS6 normalized blood glucose and induced concomitant increases in β cell proliferation and β cell number. Affinity pulldown and kinase profiling studies implicate Erb3 binding protein-1 and the IκB kinase pathway in the mechanism of action of WS6.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23330637 DOI: 10.1021/ja309304m
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419